NPM1 and acute myeloid leukemia: Primary AML tumor samples were selected based on having known HLA haplotypes for HLA-A, B, C and HLA-DR, and at least one or more common recurrent mutations in either NPM1, FLT3, DNMT3A, IDH1, IDH2, KIT, or RAS from previous clinical evaluation.